Page 124 - Beam News Today

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) posted its earnings results on Wednesday. The company reported ($1.22) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.11, Briefing.com reports. Beam Therapeutics had a negative net margin of 408.13% and a negative return on equity of 43.32%. The business had revenue of […]

By Ben Glickman Shares of Verve Therapeutics surged Tuesday after revenue jumped in the third quarter. The stock was up 29% to $19.31 in afternoon trading....

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have been given a consensus rating of “Hold” by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price […]

By Rob Curran Biotech company Beam Therapeutics struck a deal with Eli Lilly to sell to the drug giant certain rights in its cardiovascular-disease...

Basketball is back in Sacramento. With a win Wednesday – and the beam lit to commemorate the occasion – downtown business owners are expecting a boost to business to start to see a welcome boost to business.

The market has nearly abandoned many of the biotech start-ups it funded in the excitement of the first Covid-19 vaccines in 2021.

Cantor Fitzgerald lowered shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from an overweight rating to a neutral rating in a research report sent to investors on Friday, Briefing.com reports. Cantor Fitzgerald also issued estimates for Beam Therapeutics’ FY2024 earnings at ($4.85) EPS. Several other equities research analysts have also weighed in on BEAM. SVB […]

Beam Therapeutics (NASDAQ:BEAM – Free Report) had its price objective cut by Cantor Fitzgerald from $56.00 to $32.00 in a report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts also recently issued reports about the company. Barclays reduced their price objective on Beam Therapeutics from […]

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was downgraded by equities research analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, Briefing.com reports. They presently have a $20.00 target price on the stock, down from their previous target price of […]

Beam Therapeutics Inc. said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash runway into 2026....